Effects of Folic Acid Combined with Alendronate on Bone Metabolism，CCl4 and Fibroblast Growth Factor Levels in Postmenopausal Osteoporosis Patients

Yong LIAO; Yi-yun GUO; Hong-yu ZHOU; Hai-po FENG; Gen-ding CHEN; Shui-qing YANG

doi:10.12259/j.issn.2095-610X.S20210716

Volume 42 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(7): 98-103

Yong LIAO, Yi-yun GUO, Hong-yu ZHOU, Hai-po FENG, Gen-ding CHEN, Shui-qing YANG. Effects of Folic Acid Combined with Alendronate on Bone Metabolism，CCl4 and Fibroblast Growth Factor Levels in Postmenopausal Osteoporosis Patients[J]. Journal of Kunming Medical University, 2021, 42(7): 98-103. doi: 10.12259/j.issn.2095-610X.S20210716

Citation:

Yong LIAO, Yi-yun GUO, Hong-yu ZHOU, Hai-po FENG, Gen-ding CHEN, Shui-qing YANG. Effects of Folic Acid Combined with Alendronate on Bone Metabolism，CCl4 and Fibroblast Growth Factor Levels in Postmenopausal Osteoporosis Patients[J]. Journal of Kunming Medical University, 2021, 42(7): 98-103. doi: 10.12259/j.issn.2095-610X.S20210716

Citation:

Yong LIAO, Yi-yun GUO, Hong-yu ZHOU, Hai-po FENG, Gen-ding CHEN, Shui-qing YANG. Effects of Folic Acid Combined with Alendronate on Bone Metabolism，CCl4 and Fibroblast Growth Factor Levels in Postmenopausal Osteoporosis Patients[J]. Journal of Kunming Medical University, 2021, 42(7): 98-103. doi: 10.12259/j.issn.2095-610X.S20210716

PDF( 638 KB)

Effects of Folic Acid Combined with Alendronate on Bone Metabolism，CCl4 and Fibroblast Growth Factor Levels in Postmenopausal Osteoporosis Patients

doi: 10.12259/j.issn.2095-610X.S20210716

1.
Dept. of Endocrinology of Traditional Chinese Medicine
2.
Dept. of Pathology
3.
Dept. of Gastroenterology
4.
Dept. of Respiratory Medicine，The 922 nd Hospital of the Joint Logistic Support Force of the People’s Liberation Army，Hengyang Hunan 421002，China

Received Date: 2021-04-11
Available Online: 2021-07-19
Publish Date: 2021-07-21

Abstract

Abstract

Objective To investigate the effects of folic acid combined with alendronate sodium on bone metabolism, CCL4 and fibroblast growth factor levels in postmenopausal osteoporosis patients. Methods A total of 154 postmenopausal osteoporosis patients admitted to our hospital from January 2017 to January 2019 were selected as the research objects and randomly divided into observation group （77 cases） and control group （77 cases）. The control group was given calcium combined with alendronate sodium treatment, and the observation group added oral folic acid tablets to the control group. The two groups of patients were treated continuously for 6 months. The total effective rate and fracture rate of the two groups were compared. The bone mineral density, 25-OHD, CTX, BALP, BGP, CCL4, FGF-21, FGF-23, VAS pain score and SF-36 quality of life score were compared between the two groups before and after treatment. Results The total effective rate and fracture rate in the observation group were 89.61% and 1.30%, respectively, and in the control group were 67.54% and 5.19%. The difference between the two groups was statistically significant （P < 0.05）. Before the treatment, there was no statistical difference between the two groups of L1-4, femoral neck, femoral tuberosity bone mineral density, 25-OHD, CTX, BALP, BGP, CCL4, FGF-21, FGF-23 levels, and VAS and SF-36 scores. （P > 0.05）. After the treatment, the two groups of L1-4, femoral neck, femoral tuberosity bone mineral density, 25-OHD levels and SF-36 score increased, while CTX, BALP, BGP, CCL4, FGF-21, FGF-23 levels and VAS score decreased （P < 0.05）. Compared with the control group, the observation group had higher L1-4, femoral neck, femoral tuberosity bone mineral density, 25-OHD level and SF-36 score, while CTX, BALP, BGP, CCL4, FGF-21, FGF-23 level and VAS score were lower （P < 0.05）. Conclusion Folic acid combined with alendronate sodium has a significant clinical effect in the treatment of postmenopausal osteoporosis patients, and can improve the bone mineral density, bone metabolism, CCL4 and fibroblast growth factor levels.
- Folic acid,
- Alendronate sodium,
- Postmenopausal,
- Osteoporosis,
- Bone metabolism,
- CCL4,
- Fibroblast growth factor

FullText(HTML)

References(23)

References

[1]	Nakamura K,Saito T,Kobayashi R,et al. Physical activity modifies the effect of calcium supplements on bone loss in perimenopausal and postmenopausal women:subgroup analysis of a randomized controlled trial[J]. Arch Osteoporos,2019,14(1):17. doi: 10.1007/s11657-019-0575-4
[2]	Wang Y C,Chiang J H,Hsu H C,et al. Decreased fracture incidence with traditional Chinese medicine therapy in patients with osteoporosis:A nationwide population-based cohort study[J]. BMC Complement Altern Med,2019,19(1):42. doi: 10.1186/s12906-019-2446-3
[3]	Gao S T,Lv Z T,Zhou C K,et al. Association between IGF-1 polymorphisms and risk of osteoporosis in Chinese population:A meta-analysis[J]. BMC Musculoskelet Disord,2018,19(1):141. doi: 10.1186/s12891-018-2066-y
[4]	Shen J,Fu S,Song Y. Relationship of fibroblast growth factor 23(FGF-23)serum levels with low bone mass in postmenopausal women[J]. J Cell Biochem,2017,118(12):4454-4459. doi: 10.1002/jcb.26101
[5]	Nakamura Y,Suzuki T,Kamimura M,et al. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment[J]. Bone Res,2017,5(4):17021.
[6]	Ching-Yun C,Kuo-Yun T,Yen-Liang L,et al. Overexpression of insulin-like growth factor 1 enhanced the osteogenic capability of aging bone marrow mesenchymal stem cells[J]. Theranostics,2017,7(6):1598-1611. doi: 10.7150/thno.16637
[7]	Yoon B K,Lee D Y,Park M C,et al. Effects of combination therapy of alendronate and hormonal therapy on bone mineral density in postmenopausal Korean Women:Multicenter,randomized controlled clinical trial[J]. J Korean Med Sci,2017,32(6):992-998. doi: 10.3346/jkms.2017.32.6.992
[8]	El M A,Chozlani I,Mounach A,et al. Homocysteine,folate,and vitamin B12 levelsand verltebral fracture risk inpostmenopausal women[J]. J Clin Densitometry,2012,15(3):328-333. doi: 10.1016/j.jocd.2011.12.001
[9]	王平. 阿仑膦酸钠联合阿法骨化醇对绝经后骨质疏松症患者骨密度、骨代谢指标及细胞因子的影响[J]. 临床合理用药,2020,13(9A):24-26.
[10]	张智海,刘忠厚,李娜,等. 中国人骨质疏松症诊断标准专家共识(第三稿·2014 版)[J]. 中国骨质疏松杂志,2014,20(9):1007-1010. doi: 10.3969/j.issn.1006-7108.2014.09.001
[11]	Snow S,Kirwan J R. Visual analogue scales:a source of error[J]. Ann Rheum Dis,1988,47(6):526. doi: 10.1136/ard.47.6.526
[12]	E Ware Jr , C D Sherbourne. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection[J]. Med Care,1992,30(6):473-483.
[13]	郑筱萸. 中药新药临床研究指导原则（试行）[M]. 北京: 中国医药科技出版社, 2002: 184.
[14]	邱奕雁,陈鹏飞,陈扬,等. 阿仑膦酸钠片联合阿法骨化醇胶囊治疗围绝经期骨质疏松的临床研究[J]. 中国临床药理学杂志,2017,33(6):496-498.
[15]	袁志峰,刘会文. 唑来膦酸、伊班膦酸钠及阿伦膦酸钠防治绝经后骨质疏松症的疗效对比研究[J]. 中国骨质疏松杂志,2018,24(2):249-252,269. doi: 10.3969/j.issn.1006-7108.2018.02.023
[16]	赵蕾,王立,鲁梅花,等. 唑来膦酸与阿仑膦酸钠治疗绝经后骨质疏松症的效果和安全性比较[J]. 中国综合临床,2017,33(12):1134-1137. doi: 10.3760/cma.j.issn.1008-6315.2017.12.019
[17]	董占玲. 唑来膦酸与阿仑膦酸钠治疗老年骨质疏松症的临床对比[J]. 中国老年保健医学,2018,16(6):80-82. doi: 10.3969/j.issn.1672-2671.2018.06.033
[18]	Doshi S N,McDowell I F,Moat S J,et al. Folic acid improves endothelial function in coronary arlery disease viamechanism largely independent of homocysteine lowering[J]. Circulation,2002,105(1):22-26. doi: 10.1161/hc0102.101388
[19]	张德春,陈姬. 叶酸联合阿仑膦酸钠及钙剂治疗老年男性骨质疏松疗效观察[J]. 现代医药卫生,2017,33(20):3104-3108. doi: 10.3969/j.issn.1009-5519.2017.20.015
[20]	Bruzzaniti A,Baron R. Molecular regulation of osteoclast activity[J]. Rev Endocr Metab Disord,2006,7(1-2):123-139.
[21]	Fatehi F,Mollahosseini M,Hassanshahi G,et al. CC chemokines CCL2,CCL3,CCL4 and CCL5 are elevated in osteoporosis patients[J]. J Biomed Res,2017,31(5):468-470. doi: 10.7555/JBR.31.20150166
[22]	Kawai M. The FGF23/Klotho axis in the regulation of metabolichomeostasis[J]. Horm Mol Biol Clin Investig,2016,28(1):55-67.
[23]	Hui X,Feng T,Liu Q,et a1. The FGF21-adiponectin axis in controllingenergy and vascular homeostasis[J]. J Mol Cell Biol,2016,8(2):110-119. doi: 10.1093/jmcb/mjw013

Relative Articles(20)

Relative Articles

[1]	Lirong GUO, Xiang LIU, Jiahao LI, Ying ZHANG. Predicting Active Components of Chinese Herbal Medicines for Treating Bone Aging Based on Reverse Network Pharmacology and Molecular Docking. Journal of Kunming Medical University, 2026, 47(): 1-14.
[2]	Dan MA, Yajuan ZHANG, Binbin MA, Qiaoning YUE, Jianping LIU. Genomic Analysis of Cellular Senescence and Osteoporosis Target Genes and Small Molecule Screening. Journal of Kunming Medical University, 2025, 46(2): 141-150. doi: 10.12259/j.issn.2095-610X.S20250220
[3]	Leijing RAN, Shaohua WANG, Lintong LI, Li GUI. A Meta-analysis of the Effect of Adjuvant Probiotics in Patients with Osteoporosis. Journal of Kunming Medical University, 2024, 45(2): 65-76. doi: 10.12259/j.issn.2095-610X.S20240209
[4]	Yongyi ZOU, Zhiye QI, Dongmei SUN, Chunmei Wan, Kun LIANG. Effects of Different Vitamin D Doses on Bone Metabolism and Growth and Development Indicators of Preterm infants：A Cohort Study. Journal of Kunming Medical University, 2023, 44(11): 76-81. doi: 10.12259/j.issn.2095-610X.S20231111
[5]	Yu-wei JI, Xin ZHAO, Jiang-li LU, Yi YANG, Wei TANG, Jian-lin JIAO. Effect of Osteoking on Bone Density and Bone Biomechanics of Tree Shrews in a Postmenopausal Osteoporotic Fracture Model. Journal of Kunming Medical University, 2020, 41(11): 7-11. doi: 10.12259/j.issn.2095-610X.S20201103
[6]	Li Na , Fang Hong Li , Deng Li. . Journal of Kunming Medical University, 2019, 40(06): 135-139.
[7]	Jie Chun Lin , Yue Qiao Ning , Teng Zhao Wei . . Journal of Kunming Medical University, 2019, 40(01): 1-5.
[8]	Du Shi Gang , Zhao Ling , Pu Meng Xian , Pan Yi , Du Juan , Ke Ting Yu . . Journal of Kunming Medical University, 2018, 39(12): 43-48.
[9]	Li Jin Tao , Zheng Hong , Tang Wei , Wu Chao , Jiao Jian Lin , Zhao Hong Bin . Effects of Different Feeding Space on Estradiol and Bone Metabolism Index in Tree Shrews with Osteoporosis. Journal of Kunming Medical University, 2017, 38(09): 1-6.
[10]	Li Jin Tao , Zheng Hong , Li Bo , Yuan Xin , Tang Wei , Zhao Hong Bin . Effects of Osteoking on Estradiol and Bone Metabolism of Tree Shrews with Osteoporotic Fracture. Journal of Kunming Medical University, 2017, 38(11): 15-18.
[11]	Zhao Zheng Xing . Clinical Efficacy of PFNA Internal Fixation in the Treatment of 40 Osteoporotic Intertrochanteric Fractures. Journal of Kunming Medical University,
[12]	Li Li . Effect of Geraniin on Expression of Wnt3a in BMSC from Osteoporotic Rats. Journal of Kunming Medical University,
[13]	Yang Feng . Establishment of Tree Shrew Osteoporosis Model by Bilateral Ovariectomy. Journal of Kunming Medical University,
[14]	Cai Jin Feng . . Journal of Kunming Medical University,
[15]	Yao Rong Cheng . . Journal of Kunming Medical University,
[16]	Yang Man . . Journal of Kunming Medical University,
[17]	Yu Le . . Journal of Kunming Medical University,
[18]	Lv Tao . . Journal of Kunming Medical University,
[19]	Yuan Xiao Feng . . Journal of Kunming Medical University,
[20]	Zhang Xiao Chao . . Journal of Kunming Medical University, 2012, 33(08): 1-1.